Nearly a thing of the past
“Super Asprin” makes it’s mark.
John Gilmer has broken through the aspirin barrier to form this “Super Asprin”. He is now apparently in talks with Solvatrin Theraputics regarding developing the drug.
Solvatrin Theraputics are the company behind what has now been named as “Super Aspirin”, and are in talks with a number of multinational pharma companies.
Based in Cork, the company expects the super product to be “on the shelf” in the next two years. Regulatory approval pending, the sale are set to top €500m in the space of 8 years!
Dr John Gilmer has spent in excess of 10 years working on the “Super Aspirin” believes it will give you all the benefits of aspirin but not the gastro-intestinal bleeding side effect. In order to protect the intestine and stomach lining, Gilmer discovered that he could deactivate the aspirin and re-activate at a later stage by enzymes naturally present in the blood. Basically, the aspirin content content becomes active as soon as it reaches the bloodstream.
“Our research has shown the market demands a solution to the side effects of aspirin and our drug directly addresses this problem” says c0-founder Pat O’Flynn.
It appears that June is a good month for Research, Development and Pharmaceuticals – Gilmer’s 10 years hard work has finally paid off
